This website is intended only for United States healthcare professionals; if you are not a United States healthcare professional, please visit www.BioMarin.com
This website was developed and funded by BioMarin and is intended for healthcare professionals only. It offers a non-exhaustive selection of materials, including but not limited to publications, presentations, posters and educational materials, to support scientific exchange.
Clinical study results reflect knowledge at the study’s completion and may not be current. Review the methodology, limitations, and authors’ financial disclosures for details.
The information on this website is not medical advice and should not replace independent medical judgment or further research. Content on investigational therapeutics or uses of approved products does not confirm safety or efficacy. BioMarin does not endorse off-label use of its medicines.
As product information may vary by country, please refer to your local health authority regulations and respective approved product information for indications and safety details.

As of May 29th, 2026, BioMarin has voluntarily withdrawn ROCTAVIAN (valoctocogene roxaparvovec-rvox) from the market

Congress Posters & Presentations

Access Hemophilia A related posters and presentations from recent congresses.

Hemophilia A

Filter
Filter by:
Filter by:
Filter by year:

Congress Posters and Presentations

Access posters and presentations from recent congresses. All displayed posters and presentations are protected by copyright and are intended for individual use only.
Please Note: Poster content may be unavailable or delayed. This could be due to copyright or embargo guidelines.
You may check back later or contact medinfo@bmrn.com or complete a request form to inquire about this specific material

Poster

  • Congresses
  • Hemophilia A
  • GTH
  • 2026

Impact of gene therapy on the hemophilia-free mind: Outcomes before and after valoctocogene roxaparvovec in GENEr8-1 trial participants

Poster

  • Congresses
  • Hemophilia A
  • GTH
  • 2026

Final analysis of the phase 1/2 trial of valoctocogene roxaparvovec for severe hemophilia A

Presentation

  • Congresses
  • Hemophilia A
  • GTH
  • 2026

Efficacy, safety, and quality of life 5 years after valoctocogene roxaparvovec gene transfer

Presentation

  • Congresses
  • Hemophilia A
  • EAHAD
  • 2026

Characterization of ALT elevations during the 5-year GENEr8-1 trial of valoctocogene roxaparvovec gene transfer for severe hemophilia A

Presentation

  • Congresses
  • Hemophilia A
  • BIC
  • 2025
  • Safety Profile and Efficacy

Safety and efficacy of valoctocogene roxaparvovec in participants with active or prior FVIII inhibitors: Results from a phase 1/2 trial

Presentation

  • Congresses
  • Hemophilia A
  • ISTH
  • 2025

Steady Musculoskeletal Health After Gene Therapy in Severe Hemophilia A: 5-Year Results

Poster

  • Congresses
  • Hemophilia A
  • HEMO
  • 2024
  • Patient Reported Outcomes
  • Safety Profile and Efficacy

Bleeding rate, FVIII utilization, corticosteroid use, quality of life and safety 4 years after gene transfer with valoctocogene roxaparvovec in a Brazilian cohort: Results from GENEr8-1

Poster

  • Congresses
  • Hemophilia A
  • WFH
  • 2024
  • Patient Reported Outcomes
  • Safety Profile and Efficacy

Health-related quality of life improvements following valoctocogene roxaparvovec gene therapy in people without bleeds or target joints at baseline: a post hoc analysis from GENEr8-1

Poster

  • Congresses
  • Hemophilia A
  • ASH
  • 2023
  • Safety Profile and Efficacy

Bleeding Outcomes in Participants With Factor VIII Activity <5 IU/dL Post-Gene Transfer in GENEr8-1

Presentation

  • Congresses
  • Hemophilia A
  • ISTH
  • 2022
  • Safety Profile and Efficacy

Hemostatic results for up to 6 years following treatment with valoctocogene roxaparvovec, an AAV5-hFVIII-SQ gene therapy for severe hemophilia A